Login Register Cart 0
Review Article

喹啉类似物生物活性和临床研究的新趋势：综述

卷 23, 期 5, 2022

发表于: 28 March, 2022

页: [441 - 457] 页: 17

弟呕挨: 10.2174/1389450122666210415100151

价格: $65

摘要

存在于多个分子中的喹啉环具有多种生物活性。因此，该环存在于临床前和临床研究中几种候选药物的结构组成中；因此，有必要汇总这些结果以促进新药的设计。出于这个原因，本综述选择了一些化合物的活性进行检查，例如抗疟、抗菌、抗癌、抗炎、抗糖尿病、抗风湿和抗病毒活性。所选科学文章的所有出版物都在 2000 年至 2020 年之间发表。除了介绍一些天然和合成化合物的结构及其活性外，我们还列出了含有喹啉核的抗疟药物的 III 期和 IV 期临床研究和 III 期羟氯喹和氯喹的临床研究，以评估它们在 COVID-19 中的可能作用。最后，我们回顾了一些作用机制，以及一些喹啉衍生物的副作用。

关键词: 临床试验，喹啉环，抗疟药，COVID-19，药理学，氯喹。

« Previous Next »
图形摘要

[1]
Joshi SD, Jangade NM, Dixit SR, Joshi AS, Kulkarni VH. Quinoline: a promising and versatile scaffold for future. Indo Amer J Pharm Res 2016; 6(04): 5033-44.
[2]
Simões CMO, Schenkel EP, Gosmann G, Mello JCP, Mentz LA, Petrovick PR. Pharmacognosy: from plant to drug Porto Alegre 2003; 765-80.
[3]
Manzali de Sá I. Resistance to chloroquine and the search for antimalarials between the 1960s and 1980s. Hist Cienc Saude Manguinhos 2011; 18(2): 407-30.
[4]
World Health Organization; Available from:. https://www. mmv.org/sites/default/files/uploads/docs/publications/World%20Malaria%20Report_0.pdf (Accessed January 2021).
[5]
Çapcı A, Lorion MM, Wang H, et al. Artemisinin-(Iso)quinoline hybrids by C-H activation and click chemistry: combating multidrug-resistant malaria. Angew Chem Int Ed Engl 2019; 58(37): 13066-79.
[http://dx.doi.org/10.1002/anie.201907224] [PMID: 31290221]
[6]
Freedman A. Chloroquine and rheumatoid arthritis; a short-term controlled trial. Ann Rheum Dis 1956; 15(3): 251-7.
[http://dx.doi.org/10.1136/ard.15.3.251] [PMID: 13363258]
[7]
Othman DIA, Selim KB, El-Sayed MAA, et al. Design, synthesis and anticancer evaluation of new substituted thiophene-quinoline derivatives. Bioorg Med Chem 2019; 27(19) ,115026.
[http://dx.doi.org/10.1016/j.bmc.2019.07.042] [PMID: 31416740]
[8]
Musharrafieh R, Kitamura N, Hu Y, Wang J. Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. Bioorg Chem 2020; 101 ;103981.
[http://dx.doi.org/10.1016/j.bioorg.2020.103981] [PMID: 32559580]
[9]
Gao P, Wang L, Zhao L, et al. Anti-inflammatory quinoline alkaloids from the root bark of Dictamnus dasycarpus. Phytochemis 2020; 172 ;112260.
[http://dx.doi.org/10.1016/j.phytochem.2020.112260] [PMID: 31982646]
[10]
Singh SK, Singh S. A brief history of quinoline as antimalarial agents. Int J Pharm Sci Rev Res 2014; 25(1): 295-302.
[11]
Cunico W, Carvalho SA, Gomes CRB, Marques CH. Anti-malarial drugs-history and perspectives. Revista Brasileira de Famácia 2008; 89(1): 49-55.
[12]
Han X, Lamshöft M, Grobe N, et al. The biosynthesis of papaverine proceeds via (S)-reticuline. Phytochemistry 2010; 71(11-12): 1305-12.
[http://dx.doi.org/10.1016/j.phytochem.2010.04.022] [PMID: 20494383]
[13]
Anderberg PI, Harding MM, Lay PA. The effect of metal ions on the electrochemistry of the antitumor antibiotic streptonigrin. J Inorg Biochem 2004; 98(5): 720-6.
[http://dx.doi.org/10.1016/j.jinorgbio.2003.10.011] [PMID: 15134917]
[14]
Olajide OA, Ajayi AM, Wright CW. Anti-inflammatory properties of cryptolepine. Phytother Res 2009; 23(10): 1421-5.
[http://dx.doi.org/10.1002/ptr.2794] [PMID: 19288476]
[15]
World Health Organization; Available from:. https://apps.who. int/iris/bitstream/handle/10665/275867/9789241565653-eng.pdf? ua=1 (Accessed July 2019).
[16]
Soares RR, da Silva JM, Carlos BC, et al. New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. Bioorg Med Chem Lett 2015; 25(11): 2308-13.
[http://dx.doi.org/10.1016/j.bmcl.2015.04.014] [PMID: 25920564]
[17]
Kumar S, Bawa S, Gupta H. Biological activities of quinoline derivatives. Mini Rev Med Chem 2009; 9(14): 1648-54.
[http://dx.doi.org/10.2174/138955709791012247] [PMID: 20088783]
[18]
Ghorab MM, Alsaid MS. Anti-breast cancer activity of some novel quinoline derivatives. Acta Pharm 2015; 65(3): 271-83.
[http://dx.doi.org/10.1515/acph-2015-0030] [PMID: 26431105]
[19]
Bispo MLF, Alcantara CC, Moraes MO, et al. A new and potent class of quinoline derivatives against câncer. Monatsh Chem 2015; 146: 2041-52.
[http://dx.doi.org/10.1007/s00706-015-1570-0]
[20]
Srikanth L, Raghunandan N, Siriniva P, Amarender RG. Synthesis and evaluation of newer quinoline derivatives of Thiazolidinediones for their antidiabetic activity. Int J Pharm Bio Sci 2010; 1(4)
[21]
Edmont D, Rocher R, Plisson C. chenault J. Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents. Bioorg Med Chem Lett 2000; 10(16): 1831-4.
[22]
Rogachev AD, Kuranov SO, Salakhutdinov NF. Chemical approach to the design of affective antidiabectic agents. Russian Chem Rev 2016; 85(12): 1313-37.
[23]
Souza MVN, Almeida MV, Silva AD, Couri MRC. Ciprofloxacina, uma importante fluorquinolona no combate ao antraz. Rev Bras Farm 2004; 85(1): 13-8.
[24]
Shivaraj Y, Naveen MH, Vijayakumar GR, Kumar DBA. Design, synthesis and antibacterial activity studies of novel quinoline carboxamide derivatives. J Korean Chem Soc 2013; 2: 241-5.
[http://dx.doi.org/10.5012/jkcs.2013.57.2.241]
[25]
Sumana T, Iyengar P, Sanjeevarayappa C. Synthesis, characterization and antimicrobial activity of pharmaceutically important 1,2-dihydroquinoline derivatives. J Appl Chem 2015; 4(3): 818-27.
[26]
Zarghi A, Ghodsi R, Azizi E, Daraie B, Hedayati M, Dadrass OG. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. Bioorg Med Chem 2009; 17(14): 5312-7.
[http://dx.doi.org/10.1016/j.bmc.2009.05.084] [PMID: 19560931]
[27]
Mazzoni O, Esposito G, Diurno MV, et al. Synthesis and pharmacological evaluation of some 4-oxoquinoline-2-carboxylic acid derivatives as anti-inflammatory and analgesic agents. Arch Pharm Chem Life Sci 2010; 10: 561-9.
[http://dx.doi.org/10.1002/ardp.201000016]
[28]
Wen X, Wang S, Liu D, Gong G, Quan Z. Synthesis and evaluation of the anti-inflammatory activity of quinoline derivatives. Med Chem Res 2015; 24: 2591-603.
[http://dx.doi.org/10.1007/s00044-015-1323-y]
[29]
de Meneses Santos R, Barros PR, Bortoluzzi JH, et al. Synthesis and evaluation of the anti-nociceptive and anti-inflammatory activity of 4-aminoquinoline derivatives. Bioorg Med Chem 2015; 23(15): 4390-6.
[http://dx.doi.org/10.1016/j.bmc.2015.06.029] [PMID: 26116178]
[30]
Mukherjee S, Pal M. Quinolines: a new hope against inflammation. Drug Discov Today 2013; 18(7-8): 389-98.
[http://dx.doi.org/10.1016/j.drudis.2012.11.003] [PMID: 23159484]
[31]
Buckley GM, Cooper N, Dyke HJ, et al. 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma. Bioorg Med Chem Lett 2002; 12(12): 1613-5.
[http://dx.doi.org/10.1016/S0960-894X(02)00223-8] [PMID: 12039574]
[32]
Billah M, Buckley GM, Cooper N, et al. 8-Methoxyquinolines as PDE4 inhibitors. Bioorg Med Chem Lett 2002; 12(12): 1617-9.
[http://dx.doi.org/10.1016/S0960-894X(02)00224-X] [PMID: 12039575]
[33]
Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2(5): 364-71.
[http://dx.doi.org/10.1038/nri802] [PMID: 12033742]
[34]
Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23(2)(Suppl. 1): 82-91.
[http://dx.doi.org/10.1016/S0049-0172(10)80012-5] [PMID: 8278823]
[35]
Silva JC, Mariz HA, Rocha LF Jr, et al. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (São Paulo) 2013; 68(6): 766-71.
[http://dx.doi.org/10.6061/clinics/2013(06)07] [PMID: 23778483]
[36]
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 2018; 6: 15.
[http://dx.doi.org/10.1038/s41413-018-0016-9]
[37]
Li C, Zhu X, Ji X, et al. Chloroquine, a FDA-approved drug, prevents zika virus infection and its associated congenital microcephaly in mice. Ebiomedicine 2017; 24: 189-94.
[PMID: 29736302]
[38]
Bedoya LM, Abad MJ, Calonge E, et al. Quinoline-based compounds as modulators of HIV transcription through NF-κB and Sp1 inhibition. Antiviral Res 2010; 87(3): 338-44.
[http://dx.doi.org/10.1016/j.antiviral.2010.06.006]
[39]
Perin N, Alic J, Liekens S, et al. Different positions of amide side chains on the benzimidazo[1,2-a]quinoline skeleton strongly influence biological activity. N J Chem 2018; 42(9): 7096-104.
[40]
Shang X, Morris-Natschke SL, Liu Y, et al. Biologically active quinoline and quinazoline alkaloids part I. Med Res Rev 2017; 38(3): 775-828.
[41]
Evaluating the efficacy of chloroquine for the treatment of Plasmodium vivax infections in Central Vietnam. National Institute of Malariology, Parasitology and Entomology, Vietnam 2016. Available from:. https://clinicaltrials.gov/ct2/show/NCT02610686
[42]
Pharmacokinetic study of multi-dose chloroquine 2014. Available from:. https://clinicaltrials.gov/ct2/show/NCT01814423?term=Chl oroquine&phase=23&rank=4 (Accessed February 2019).
[43]
Extended-dose C. hloroquine (ECQ) for resistant falciparum malaria among Afghan Refugees in Pakistan (ECQNWFP). 2009. Available from:. https://clinicaltrials.gov/ct2/show/NCT01019408? term=Chloroquine&phase=23&rank=13 (Accessed February 2019).
[44]
Chloroquine for treatment of glioblastoma multiforme. 2009. Available from:. https://clinicaltrials.gov/ct2/show/NCT00224978? term=Chloroquine&phase=23&rank=18 (Accessed February 2019).
[45]
Prevention of P. vivax malaria during pregnancy in bolivia. 2013. Available from: . https://clinicaltrials.gov/ct2/show/NCT00290420? term=Chloroquine&phase=23&rank=21 (Accessed February 2019).
[46]
Cura Chik. A trial of the efficacy and safety of chloroquine as therapeutic treatment of chikungunya disease 2015.Available from:. https://clinicaltrials.gov/ct2/show/NCT00391313?term=Chloroquine&phase=23&rank=2 (Accessed February 2019).
[47]
Estimating the risk of Plasmodium vivax relapses in Afghanistan (VRA). 2019. Available from:. https://clinicaltrials.gov/ct2/show/ NCT01178021?term=Chloroquine&phase=23&rank=27 (Accessed February 2019).
[48]
Pharmacoepidemiological evaluation of autophagy inhibition in treatment of HCV Patients resistant to standard therapy. Pilot Study 2015. Available from:. https://clinicaltrials.gov/ct2/show/ NCT02058173?term=Chloroquine&phase=23&rank=39 (Accessed February 2019).
[49]
Efficacy study of hydroxychloroquine to treat high-risk coronary artery disease. CHANGAN 2017. Available from:. https://clinical trials.gov/ct2/show/NCT02874287?term=hydroxychloroquine& phase=23&rank=1
[50]
Hydroxychloroquine for the prevention of cardiovascular events in myocardial infarction Patients - a Safety Pilot Trial (OXI). 2018. Available from:. https://clinicaltrials.gov/ct2/show/NCT02648464? term=hydroxychloroquine&phase=23&rank=2 (Accessed February 2019).
[51]
Hydroxychloroquine treatment of dry eyes in patients with primary sjögren's syndrome. 2013. Available from:. https://clinicaltrials. gov/ct2/show/NCT01601028?term=hydroxychloroquine&phase=2 3&rank= (Accessed February 2019).
[52]
Hydroxychloroquine for prevention of recurrent miscarriage. 2019. Available from:. https://clinicaltrials.gov/ct2/show/NCT 03165136?term=hydroxychloroquine&phase=23&rank=4 (Accessed February 2019).
[53]
Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome (PAPIRUS). 2018. Available from:. https://clinicaltrials.gov/ct2/show/NCT03540810? term=hydroxychloroquine&phase=23&rank=5(Accessed February 2019).
[54]
[54] Hydroxychloroquine for the first thrombosis prevention in antiphospholipid antibody positive patients. 2017. Available from:. https://clinicaltrials.gov/ct2/show/NCT01784523?term=hydroxychloroquine&phase=23&rank=6(Accessed February 2019).
[55]
Hydroxychloroquine to improve insulin sensitivity in rheumatoid arthritis (RA PLUS). 2014. Available from:. https://clinicaltrials. gov/ct2/show/NCT01132118?term=hydroxychloroquine&phase=23&rank=7(Accessed February 2019).
[56]
Reducing risk of type 2 diabetes: hydroxychloroquine use in prediabetes. 2016. Available from:. https://clinicaltrials.gov/ct2/show/NCT01326533?term=hydroxychloroquine&phase=23&rank=8 (Accessed February 2019).
[57]
Hydroxychloroquine versus placebo in primary sjögren's syndrome (JOQUER). 2012. Available from:. https://clinicaltrials. gov/ct2/show/NCT00632866?term=hydroxychloroquine&phase=23&rank=9 (Accessed February 2019).
[58]
Hydroxychloroquine and cognitive function after surgery. 2018. Available from:. https://clinicaltrials.gov/ct2/show/NCT03025087? term=hydroxychloroquine&phase=23&rank=1 (Accessed February 2019).
[59]
Hydroxychloroquine sulfate for reduction of proteinuria in patients with IgA Nephropathy: a Self- Controlled Study. 2013. Available from:. https://clinicaltrials.gov/ct2/show/NCT02351752?term=hydroxychloroquine&phase=23&rank=13 (Accessed February 2019).
[60]
Effect of hydroxychloroquine on atrial fibrillation recurrence. 2018. Available from:. https://clinicaltrials.gov/ct2/show/NCT03592823?term=hydroxychloroquine&phase=23&rank=15 (Access ed February 2019).
[61]
Multicenter study assessing the efficacy & safety of hydroxychloroquine sulfate in patients with systemic lupus erythematosus or cutaneous lupus erythematosus with active lupus erythematosus specific skin lesion 2014. Available from:. https://clinicaltrials. gov/ct2/show/NCT01551069?term=hydroxychloroquine&phase=23&rank=16 (Accessed February 2019).
[62]
Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss; 2018.Available from:. https://clinicaltrials.gov/ct2/show/NCT03305263? term=hydroxychloroquine&phase=23&rank=17 (Accessed February 2019).
[63]
Hydroxychloroquine in giant cell arteritis. 2015. Available from:. https://clinicaltrials.gov/ct2/show/NCT00430807?term=hydroxychloroquine&phase=23&rank=18 (Accessed February 2019).
[64]
The reduction of systemic lupus erythematosus flares: Study PLUS. 2011. Available from:. https://clinicaltrials.gov/ct2/show/NCT00413361?term=hydroxychloroquine&phase=23&rank=19 (Accessed February 2019).
[65]
Plaquenil for alopecia areata, alopecia totalis. 2009. Available from:. https://clinicaltrials.gov/ct2/show/NCT00176982?term=hydroxychloroquine&phase=23&rank=21 (Accessed February 2019).
[66]
Pharmacological treatment in osteoarthritis (FABIO). 2015. Available from:. https://clinicaltrials.gov/ct2/show/NCT01148043? term=hydroxychloroquine&phase=23&rank=23 (Accessed February 2019).
[67]
Efficacy of intrarectal versus intravenous quinine for the treatment of childhood cerebral malaria. 2005. Available from:. https://clinicaltrials.gov/ct2/show/NCT00124267?term=quinine&phase=23&rank=6 (Accessed February 2019).
[68]
A bioequivalence study comparing camoquin® suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects. 2010. Available from:. https://clinicaltrials.gov/ct2/show/NCT00859807?term=amodiaquine&phase=23&rank=4 (Accessed February 2019).
[69]
Single Low-dose primaquine Efficacy and Safety. 2017. Available from:. https://clinicaltrials.gov/ct2/show/NCT02090036?titles=Single+Low-dose+primaquine+Efficacy+and+Safety&rank=2 (Access ed February 2019).
[70]
Investigation of short course, high dose primaquine treatment for liver stages of plasmodium vivax infection. 2015. Available from:. https://clinicaltrials.gov/ct2/show/NCT02364583?titles=Investigation+of+Short+Course%2C+High+Dose+primaquine&rank=1 (Accessed February 2019).
[71]
A trial on supervised primaquine use in Ethiopia. 2016. Available from:. https://clinicaltrials.gov/ct2/show/NCT02793388?titles=A+Trial+on+Supervised+Primaquine+Use+in+Ethiopia&rank=1 (Accessed February 2019).
[72]
Evaluation of the gametocytocidal efficacy and safety of primaquine in uncomplicated Falciparum Malaria in Uganda. 2011. Available from:. https://clinicaltrials.gov/ct2/show/NCT01365598? titles=Evaluation+of+the+Gametocytocidal+Efficacy+and+Safety+of+Primaquine+in+Uncomplicated+Falciparum+Malaria+in+Ug anda&rank=1 (Accessed February 2019).
[73]
Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV. In vitro inhibition of severe acute respiratoy syndrome coronavirus by chloroquine. In: Biochemcial and Biophysical Research Communications. 2004; pp. 264-8.
[74]
Vincent MJ, Bergeron E, Erickson BR, et al. Chloroquine is a potente inhibitor of SARS coronavirus infection and spread. Virol J 2005; 1-10.
[75]
Marella A, Tanwar OP, Saha R, et al. Quinoline: A versatile heterocyclic. Saudi Pharm J 2013; 21(1): 1-12.
[http://dx.doi.org/10.1016/j.jsps.2012.03.002] [PMID: 23960814]
[76]
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: randomized controlled, open-label, phase 3 clinical trial. Avaialble from:. https://clinicaltrials.gov/ct2/show/ NCT04414241?term=Hydroxychloroquine&cond=SARS-COV-2 &phase=2&draw=2&rank=1 (Accessed July 2020).
[77]
A study of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2(HOPETrial). Available from:. https://clinicaltrials. gov/ct2/show/NCT04330144?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=4 (Accessed July 2020).
[78]
A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of oral hydroxychloroquine for the treatment of SARS-CoV-2 positive patients for the prevention of severe COVID-19 Disease. Available from:. https://clinicaltrials.gov/ct2/show/NCT04329611?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=7 (Accessed July 2020).
[79]
Hydroxychloroquine efficacy and safety in preventing SARSCoV- 2 Infection and COVID-19 disease severity during pregnancy. Available from:. https://clinicaltrials.gov/ct2/show/NCT04410562?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=8 (Accessed July 2020).
[80]
Immune monitoring of prophylactic effect of hydroxychloroquine in healthcare providers highly exposed to SARS-Cov-2. Available from:. altrials.gov/ct2/show/NCT04346329?term=Hydroxychloroquine&cond=SARS-COV2&phase=2&draw (Accessed July 2020).
[81]
Efficacy and safety of hydroxychloroquine for covid-19 postexposure prophylaxis of healthcare workers in the philippine general hospital and up Manila National Institutes of health: a randomized, double-blind, placebo-controlled trial. Randomized A. Available from:. https://clinicaltrials.gov/ct2/show/NCT04364815? term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw =2&rank=16 (Accessed July 2020).
[82]
Hydroxychloroquine for the treatment of mild COVID-19 Disease. Available from:. https://clinicaltrials.gov/ct2/show/NCT04340544? term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw =2&rank=18 (Accessed July 2020).
[83]
Efficacy of hydroxychloroquine (hcq) as post exposure prophylaxis (pep) for prevention of covid-19 in asymptomatic individual at risk for sars-cov-2 infection-A Open Level Control Clinical Trial. Available from:. https://clinicaltrials.gov/ct2/show/NCT04408456? term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw =2&rank=19 (Accessed July 2020).
[84]
A randomized, controlled clinical trial of the safety and efficacy of hydroxychloroquine for the treatment of COVID-19 in hospitalized patients. Available from:. https://clinicaltrials.gov/ct2/show/NCT04345692?term=Hydroxychloroquine&cond=SARS-COV-2 &phase=2&draw=2&rank=23 (Accessed July 2020).
[85]
Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 - COVID-19. 2019. Available from:. https://clinicaltrials. gov/ct2/show/NCT04342221?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=26 (Accessed July 2020).
[86]
Multicentre A. Double-blinded randomized controlled trial. preexposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the covid-19 pandemic: a multicentre, double-blinded randomized controlled trial. Available from:. https://clinicaltrials.gov/ct2/show/NCT04331834?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=27 (Accessed July 2020).
[87]
Hydroxychloroquine treatment for severe covid-19 respiratory disease: randomised clinical trial (HYDRA Trial). Available from:. https://clinicaltrials.gov/ct2show/NCT04315896?term=Hydroxychloroquine&cond=SARS-COV-2&phase==2&rank=28 (Accessed July 2020).
[88]
Safety and efficacy of post-exposure prophylaxis with hydroxychloroquine (HCQ) for the Prevention of COVID-19 in highrisk older individuals in long-term and specialized care: a doubleblind randomized control trial. Available from:. https://clinicaltrials.gov/ct2/show/NCT04397328?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=31 (Accessed July 2020).
[89]
Will hydroxychloroquine impede or prevent COVID-19: WHIP COVID-19 Study. Available from:. https://clinicaltrials.gov/ct2/show/NCT04341441?term=Hydroxychloroquine&cond=SARSCOV-2&phase=2&draw=2&rank=34 (Accessed July 2020).
[90]
Efficacy and safety of hydroxychloroquine for treatment of COVID-19. Available from:. https://clinicaltrials.gov/ct2/show/NCT04261517?term=Hydroxychloroquine&cond=SARS-COV-2 &phase=2&draw=2&rank=37 (Accessed July 2020).
[91]
Low-dose hydroxychloroquine for primary prophylaxis against SARS-CoV-2 in Health-care workers - a randomized, doubleblind. Available from:. https://clinicaltrials.gov/ct2/show/NCT04336748?term=Hydroxychloroquine&cond=SARS-COV-2& phase=2&draw=2&rank=38 (Accessed July 2020).
[92]
Chemoprophylaxis with hydroxychloroquine in healthcare personnel in contact with COVID-19 patients: a randomized controlled trial (PHYDRA Trial). Available from:. https://clinicaltrials. gov/ct2/show/NCT04318015?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=40 (Accessed July 2020).
[93]
Post exposure prophylaxis (pep) in healthcare workers exposed to COVID-19 Patients: A double-blind randomized clinical Trial. https://clinicaltrials.gov/ct2/show/NCT04437693?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=41 (Accessed July 2020).
[94]
Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID19 patients. Available from:. https://clinicaltrials.gov/ct2/show/NCT04351516?term=Hydroxychloroquine&cond=SARS-COV-2& phase=2&draw=2&rank=44 (Accessed July 2020).
[95]
Chemoprophylaxis for covid-19 infectious disease (the PROLIFIC Trial). Available from: https://clinicaltrials.gov/ct2/show/NCT04352933?term=Hydroxychloroquine&cond=SARS-COV-2& phase=2&draw=2&rank=44 (Accessed July 2020).
[96]
Randomized A. Placebo-controlled multi-site trial in Toronto, Canada. Protecting Frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis: a randomized, placebo-controlled multi-site trial in Toronto, Canada. Available from:. https://clinicaltrials.gov/ct2/show/NCT04374942?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=47 (Accessed July 2020).
[97]
Hydroxychloroquine as primary prophylaxis for COVID-19 in Healthcare Workers (HCQPreP). Available from:. clinicaltrials.gov/ct2/show/NCT04363450?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=50 (Accessed July 2020).
[98]
Assessment of the efficacy and safety of hydroxychloroquine (hcq) administered as a prophylaxis for health professionals exposed to COVID19 and working in medical intensive care units, in Tunisia. Multicentric randomized comparative study. Available from:. https://clinicaltrials.gov/ct2/show/NCT04349228?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=51 (Accessed July 2020).
[99]
Efficacy of early hydroxychloroquine in outpatients to reduce secondary hospitalisation and household transmission of COVID- 19 in Switzerland: A Double-blind, Randomised, Placebocontrolled Trial. Available from:. https://clinicaltrials.gov/ct2/show/NCT04385264?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=52 (Accessed July 2020).
[100]
A randomized phase 2/3 trial of hydroxychloroquine In Covid-19 Kinetics. Available from:. https://clinicaltrials.gov/ct2/show/NCT04353271?term=Hydroxychloroquine&cond=SARS-COV-2& phase=2&draw=2&rank=53 (Accessed July 2020).
[101]
Efficacy of hydroxychloroquine for post-exposure prophylaxis (pep) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a Blinded, Randomized Study. Available from:. https://clinicaltrials.gov/ct2/show/NCT04328961?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=54 (Accessed July 2020).
[102]
Prophylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT): a basket trial of prophylactic interventions amongst at-risk patients. Available from:. https://clinicaltrials.gov/ct2/show/NCT04389359?term=Hydroxychloroquine&cond=SARS-COV-2&pha se=2&draw=2&rank=55 (Accessed July 2020).
[103]
Hydroxychloroquine post exposure prophylaxis (pep) for household contacts of covid-19 patients: a nyc community-based randomized clinical trial. Available from:. https://clinicaltrials. gov/ct2/show/NCT04318444?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=59 (Accessed July 2020).
[104]
Outcomes related to COVID-19 treated with hydroxychloroquine among in-patients with symptomatic disease. Available from:. https://clinicaltrials.gov/ct2/show/NCT04332991?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=61 (Accessed July 2020).
[105]
Randomized A. Protecting health care workers from COVID-19 With hydroxychloroquine pre-exposure prophylaxis: a randomized, placebo-controlled trialAvailable from: https://clinicaltrials. gov/ct2/show/NCT04352946?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=62 (Accessed July 2020).
[106]
Healthcare worker exposure response and outcomes of hydroxychloroquine trial (HERO-HCQ Trial). Available from:. https://clinicaltrials.gov/ct2/show/NCT04334148?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=68 (Accessed July 2020).
[107]
Safety and efficacy of hydroxychloroquine for at risk population (sharp) against COVID-19. a cluster randomized controlled trial (SHARP COVID-19 RCT) available from:. https://clinicaltrials. gov/ct2/show/NCT04342156?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=71 (Accessed July 2020).
[108]
Prevention of COVID19 infection by the administration of hydroxychloroquine to institutionalized older people and nursing home staff. A cluster randomized controlled stepped-wedge trial (PREVICHARM Study) Available from:. https://clinicaltrials. gov/ct2/show/NCT04400019?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=72 (Accessed July 2020).
[109]
Hydroxychloroquine to prevent COVID-19 disease amongst healthcare workers (PROVIDE): a parallel randomized controlled trial. Available from: https:. https://clinicaltrials.gov/ct2/show/NCT04371523?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=74 (Accessed July 2020).
[110]
Hydroxychloroquine versus placebo in patients presenting covid- 19 infection and at risk of secondary complication: a prospective, multicentre, randomised, Double-blind Study. Available from:. https://clinicaltrials.gov/ct2/show/NCT04325893?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=76 (Accessed July 2020).
[111]
Preemptive therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada). Available from:. https://clinicaltrials.gov/ct2/show/NCT04421664?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=78 (Accessed July 2020).
[112]
Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial. Available from:. https://clinicaltrials. gov/ct2/show/NCT04328467?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=2&rank=95 (Accessed July 2020).
[113]
Post-exposure prophylaxis or preemptive therapy for SARSCoronavirus- 2: A pragmatic randomized clinical trial. Available from:. https://clinicaltrials.gov/ct2/show/NCT04308668?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=3&rank=103 (Accessed July 2020).
[114]
Randomized, double-blind, controlled trial of hydroxychloroquine vs. placebo as post-exposure prophylaxis against COVID-19 infection. Available from: https:. https://clinicaltrials.gov/ct2/show/NCT04372017?term=Hydroxychloroquine&cond=SARS-COV-2&phase=2&draw=4&rank=3 (Accessed July 2020).
[115]
An International, multi-site, bayesian platform adaptive, randomised, double-blind, placebo-controlled trial assessing the effectiveness of varied doses of oral chloroquine in preventing or reducing the severity of COVID-19 disease in healthcare workers. Available from:. https://clinicaltrials.gov/ct2/show/NCT04333732?cond=chloroquine+SARS-COV-2&phase=2&draw=2&rank=3 (Accessed July 2020).
[116]
Chloroquine for mild symptomatic and asymptomatic COVID-19 in A Two Staged, multicenter, open label and randomized trial. Available from:. https://clinicaltrials.gov/ct2/show/NCT04333628? cond=chloroquine+SARS-COV-2&phase=2&draw=2&rank=5 (Accessed July 2020).
[117]
Clinical study evaluating the efficacy of chloroquine in COVID-19 Treatment. Available from:. https://clinicaltrials.gov/ct2/show/NCT04353336?cond=chloroquine+SARS-COV-2&phase=2&draw=2&rank=6 (Accessed July 2020).
[118]
Rang HP. dale MM, Ritter JM, Moore PK. Pharmacology. Br J Clin Pharmacol 2004; 57(1): 112.
[http://dx.doi.org/10.1111/j.1365-2125.2004.01916.x]
[119]
Lewis RJ, Tsai FTF, Wigley DB. Molecular mechanisms of drug inhibition of DNA gyrase. BioEssays 1996; 18(8): 661-71.
[http://dx.doi.org/10.1002/bies.950180810] [PMID: 8760340]
[120]
Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry 2014; 53(10): 1565-74.
[http://dx.doi.org/10.1021/bi5000564] [PMID: 24576155]
[121]
Homewood CA, Warhurst DC, Peters W, Baggaley VC. Lysosomes, pH and the anti-malarial action of chloroquine. Nature 1972; 235(5332): 50-2.
[http://dx.doi.org/10.1038/235050a0] [PMID: 4550396]
[122]
Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015; 23(5): 231-69.
[http://dx.doi.org/10.1007/s10787-015-0239-y] [PMID: 26246395]
[123]
Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997; 36(7): 799-805.
[http://dx.doi.org/10.1093/rheumatology/36.7.799] [PMID: 9255117]
[124]
Tillotson GS. Quinolones: structure-activity relationships and future predictions. J Med Microbiol 1996; 44(5): 320-4.
[http://dx.doi.org/10.1099/00222615-44-5-320] [PMID: 8636945]
[125]
Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42(2): 145-53.
[http://dx.doi.org/10.1007/s12016-010-8243-x] [PMID: 21221847]
[126]
Kim JW, Kim YY, Lee H, Park SH, Kim SK, Choe JY. Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol 2017; 44(11): 1674-9.
[http://dx.doi.org/10.3899/jrheum.170158] [PMID: 28864645]

Rights & Permissions Print Cite
Article Metrics
51
1
© 2024 Bentham Science Publishers | Privacy Policy